Phenindione anticoagulant treatment during pregnancy
Meiland, H.T.; Lenstrup, C.; Wadt, J.
Ugeskrift for Laeger 149(51): 3468-3471
1987
ISSN/ISBN: 0041-5782 PMID: 3433556 Document Number: 290025
A retrospective analysis of 15 patients with acute or previous deep venous thrombosis/pulmonary embolism who recieved anticoagulants phenindione (Dindevan)/heparin during 17 pregnancies was performed. This corresponds to 1,9.permill. of all pregnancies during a period of six years. INR and APTT targets were between 2.8-4.8 and 2.0-4.0 times the upper reference limit and no further extention or relapse of the thrombo-embolism was seen. Six women developed hemorrhagic complications during pregnancy and four women had postoperative bleeding. No fetal mortality or morbidity was registered except for one suspected chondrodysplasia punctata. One women developed persistent paralysis. Based on the above, more stringet indications for phenindione anticoagulant treatment were enforced. Low dose heparin treatment was accepted after 5-10 days in cases of deep venous thrombosis. Medical prophylactic treatment was abolished during pregnancy except for constitutional high risk groups.